Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
Abstract Introduction There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson’s disease treatment. Methods The safety, pharmacokinetics, and pharmaco...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2018-10-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1007/s40120-018-0114-z |